| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Small Molecules | Endocrine System | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Small Molecules | Endocrine System | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Small Molecules | Endocrine System |
Recent Updates
Recently added Catalysts
Septerna, Inc.$35.93
-1.91 (-5.05%)
D 26Pipeline Score Richly Valued Biotech · Commercial
Market Cap
1.28 B
EPS
-0.81
P/E Ratio
-
Value Trade
8.71 M
SEC Financials
Q1 2026Dilution Risk
Revenue
26.52 M
R&D Expenses
29.54 M
Operating CF
-25.63 M
Total Assets
569.69 M
Total Liabilities
191.23 M
Equity
378.46 M
D/E Ratio
12,345
2.68 %
Week
9.29 %
1 Month
5.62 %
3 Month
19.97 %
6 Month
20.68 %
5 Year
20.68 %
All Time
Cash Data
Cash Position
347.40 M
Monthly Burn
8.54 M
Runway
38.7 mo
Burn Trend
SEC Filing
May 11, 2026
Overview
Volume
378.16 K
52 Week Range
9.11 - 32.63
% held by Insiders
39.16 %
% held by Institutions
65.67 %
Enterprise Value
954.03 M
Total Shares
45.10 M
Short %
14.42 %
Float Shares
21.88 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Septerna, Inc.
74Total events
7Upcoming
13Tier-1 (high impact)
2024 – 2027Coverage
Upcoming catalysts 7
TBD
T3Development Candidate Nomination
TSHR NAM program progressing toward development candidate selection
Event history 67
Q3 2026
◆Trial InitiationSEP-631Trial
Phase 2b trial initiation planned in CSU
chronic spontaneous urticariasource ↗
Jun 8, 2026
◆Poster PresentationSEP-479Presentation
Preclinical characterization of SEP-479 at 2026 ENDO Annual Meeting
Hypoparathyroidismsource ↗
May 12, 2026
◆Oral PresentationPresentation
Septerna to present at Bank of America Securities Health Care Conference
Apr 13, 2026
▲First Patient DosedSEP-479Trial
First participants dosed in Phase 1 SAD/MAD trial of SEP-479
hypoparathyroidismsource ↗
Apr 2026
▲First Patient DosedSEP-479Trial
Phase 1 clinical trial initiated for SEP-479
hypoparathyroidismsource ↗
Q2 2026
◆Trial InitiationSEP-631Trial
Initiate Phase 2b trial of SEP-631 in CSU
chronic spontaneous urticariasource ↗
Mar 9, 2026
▲Full ResultsSEP-631Clinical Data
Positive Phase 1 results for SEP-631 in healthy volunteers
chronic spontaneous urticariasource ↗
Mar 9, 2026
▲IND Enabling CompleteSEP-479Preclinical
Completed IND-enabling studies for SEP-479
hypoparathyroidismsource ↗
Mar 9, 2026
▲Runway Guidance UpdateCorporate
Cash runway expected to support operations at least into 2029
Mar 3, 2026
◆Oral PresentationPresentation
Septerna to present at TD Cowen 46th Annual Health Care Conference
Drug Pipeline Intelligence
D26
Pipeline Score $56M
Pipeline ValueRichly Valued
Valuation Signal2
Drugs Scored0.2x
rNPV / MCap Top 26%
Micro Cap (rank 676 of 912)
Percentile RankSepterna, Inc. faces pipeline headwinds (26/100), with $140M risk-adjusted pipeline value, led by SEP-631 in Healthy Volunteers (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SEP-631 Small molecule | Healthy Volunteers | Phase 1 | NCT07069036 | 7% | $70M | COMPLETED | 120 | FAST | C (52) | Dec 18, 2025 | LOW_RISK | MEDIUM May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
SEP-631 | chronic spontaneous urticaria | Phase 1 | 2026-05-11 | well tolerated; demonstrated a pharmacokinetic profile supportive of once-daily oral dosing; produced robust, dose-dependent suppression of icatibant-induced skin wheal formation Read More | Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneou Read More | |
SEP-631 | chronic spontaneous urticaria | Phase 1 | 2026-05-11 | well tolerated; demonstrated a pharmacokinetic profile supportive of once-daily oral dosing; produced robust, dose-dependent suppression of icatibant-induced skin wheal formation Read More | Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneou Read More | |
SEP-631 | chronic spontaneous urticaria | Phase 1 | 2026-05-11 | well tolerated; demonstrated a pharmacokinetic profile supportive of once-daily oral dosing; produced robust, dose-dependent suppression of icatibant-induced skin wheal formation Read More | Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneou Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SEPN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
SEPN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2027-01-15 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-01-15 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-01-15 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
SEPNSepterna to Present Preclinical Characterization of SEP-479, an Oral PTH1R Agonist for Hypoparathyroidism, at 2026 ENDO Annual Meeting
Septerna is set to present the preclinical characterization of SEP-479, an oral PTH1R agonist aimed at treating hypoparathyroidism. This presentation will take place at the 2026 ENDO Annual Meeting. Details about the drug's efficacy and safety profile are expected to be discussed during the event.
Read more →SEPNSepterna Highlights Business Progress and Reports First Quarter 2026 Financial Results Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneou
Septerna, Inc. has highlighted significant progress in its clinical pipeline and reported financial results for Q1 2026. The company has achieved positive Phase 1 data for SEP-631, enabling its advancement into Phase 2b trials for chronic spontaneous urticaria. Additionally, the initiation of a Phase 1 trial for SEP-479 marks a notable expansion in their experimental offerings. With a robust cash position of $522.1 million, Septerna is well-capitalized to support its operational plans through at least 2029.
Read more →SEPNSepterna to Present at Bank of America Securities Health Care Conference
Septerna, Inc. will present at the Bank of America Securities Health Care Conference on May 12, 2026. CEO Jeffrey Finer will discuss the company's advancements in G protein-coupled receptor drug discovery. The presentation will be available via a live webcast and archived for 30 days. Septerna focuses on developing therapies for unmet medical needs.
Read more →SEPNSepterna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism
Septerna has initiated a Phase 1 clinical trial for SEP-479, an oral small molecule PTH1R agonist aimed at treating hypoparathyroidism. The trial will assess safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers. Results are expected by late 2026 or early 2027, with SEP-479 potentially offering a more convenient treatment option compared to current therapies.
Read more →SEPNSepterna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chr
Septerna, Inc. reported significant milestones in its pipeline progress alongside financial results for Q4 and FY 2025. Positive Phase 1 data for SEP-631 indicates its potential in treating chronic spontaneous urticaria, with plans to initiate Phase 2b development by late 2026. Financially, the company maintains a strong cash position of $548.7 million, expected to support operations into 2029. However, increasing net losses and operational costs present challenges as the company advances its drug candidates. The pipeline also includes SEP-479, progressing toward Phase 1 initiation soon.
Read more →SEPNSepterna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy
Septerna, Inc. announced positive Phase 1 trial results for SEP-631, an oral MRGPRX2 negative allosteric modulator. The trial demonstrated effective inhibition of mast cell activation, supporting its advancement into Phase 2 for chronic spontaneous urticaria. SEP-631 was well-tolerated, with plans to explore additional mast cell-driven diseases.
Read more →SEPN▲ +10.2%on this news
Septerna to Present at TD Cowen 46th Annual Health Care Conference
Septerna, Inc. will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026. CEO Jeffrey Finer will discuss the company's advancements in G protein-coupled receptor (GPCR) drug discovery. The presentation will be available via live webcast and archived for 30 days. Septerna focuses on developing novel therapies for unmet medical needs.
Read more →SEPNSepterna Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - February 10, 2026
Septerna, Inc. has granted an inducement stock option award to Mark A. Wilson, its Chief Legal Officer, as part of its 2026 Inducement Plan. The award consists of 165,000 shares with an exercise price of $25.41, vesting over four years. This move is in compliance with Nasdaq Listing Rule 5635(c)(4) and aims to enhance the company's leadership team.
Read more →SEPNSepterna to Present Data from Phase 1 Clinical Trial of SEP-631 for the Treatment of Mast Cell-Driven Diseases at 2026 AAAAI Annual Meeting
Septerna, Inc. will present data from its Phase 1 clinical trial of SEP-631 at the 2026 AAAAI Annual Meeting. SEP-631 is a selective oral small molecule designed to target MRGPRX2 for treating chronic spontaneous urticaria and other mast cell-driven diseases. The presentation will take place on March 1, 2026, in Philadelphia.
Read more →SEPNPioneering a New Era of GPCR Drug Discovery J.P. Morgan Healthcare Conference 2026 January 2026 Nasdaq: SEPN Forward-Looking Statements This presentation contains express or implied forward looking statements of Septerna
Septerna is set to pioneer GPCR drug discovery, announcing advancements in its drug pipeline at the J.P. Morgan Healthcare Conference 2026. The company plans to initiate a Phase 1 clinical trial for its oral PTH1R agonist, SEP-479, which aims to address the unmet needs in managing hypoparathyroidism. Additionally, Septerna is collaborating with Novo Nordisk to develop oral therapies for metabolic diseases, leveraging its proprietary Native Complex Platform to enhance drug discovery capabilities. However, these forward-looking statements carry inherent risks, particularly related to regulatory processes and clinical trial outcomes.
Read more →SEPNSepterna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer
Septerna, Inc. has appointed Mark A. Wilson as Chief Legal Officer, bringing over 25 years of experience in the pharmaceutical and biotech sectors. His expertise in intellectual property and corporate governance is expected to bolster Septerna's strategic initiatives. Wilson previously held senior roles at Nektar Therapeutics and is enthusiastic about contributing to Septerna's mission in GPCR drug discovery.
Read more →SEPNSepterna to Present at 44th Annual J.P. Morgan Healthcare Conference
Septerna, Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. CEO Jeffrey Finer will discuss the company's advancements in GPCR drug discovery and its diverse pipeline of drug candidates. The presentation will be available via a live webcast on the company's website.
Read more →SEPNSepterna to Participate in 8th Annual Evercore Healthcare Conference
Septerna, Inc. will participate in the 8th Annual Evercore Healthcare Conference on December 2, 2025. The event will feature a fireside chat with management, highlighting the company's advancements in G protein-coupled receptor drug discovery. A live webcast of the presentation will be accessible on their website, with an archive available for 30 days.
Read more →SEPNSepterna Highlights Company Progress and Reports Third Quarter 2025 Financial Results
Septerna, Inc. reported significant advancements in its drug development pipeline, including the selection of SEP-479 as a leading candidate for hypoparathyroidism and the continuation of a Phase 1 trial for SEP-631 targeting mast cell-driven diseases. The company also highlighted its robust financial position, with $561.6 million expected to sustain operations through at least 2029. Upcoming milestones are anticipated in the first half of 2026.
Read more →SEPNSepterna to Participate in Upcoming Investor Conferences
Septerna, Inc. will participate in two upcoming investor conferences in November 2025. The events include a fireside chat at the Guggenheim Healthcare Innovation Conference and another at the TD Cowen Immunology & Inflammation Summit. Live webcasts will be available, showcasing Septerna's commitment to transparency and investor engagement.
Read more →SEPNSepterna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors
Septerna, Inc. has appointed Dr. Keith Gottesdiener to its Board of Directors, where he will chair a new R&D Committee. With over 30 years of experience in biotechnology, Dr. Gottesdiener's expertise is expected to bolster Septerna's efforts in advancing its GPCR-targeted therapies, particularly the PTH1R program for hypoparathyroidism. His leadership is seen as pivotal for the company's growth.
Read more →SEPN▲ +14.1%on this news
Forward-Looking Statements This presentation contains express or implied forward looking statements of Septerna, Inc. (the "Company," "we," or "our") within the meaning of the Private Securities Litigation Reform Act of
Septerna, Inc. has provided an update on its drug discovery initiatives, highlighting the advancement of its GPCR-targeted programs. The company plans to initiate Phase 1 clinical trials for its oral small molecule drug candidates, SEP-479 and SEP-631, in 2026, contingent upon successful preclinical results. Additionally, a collaboration with Novo Nordisk aims to explore oral therapies for metabolic diseases. The company emphasizes the untapped potential in GPCR drug discovery and how its Native Complex Platform is designed to overcome historical challenges in the field.
Read more →SEPN▲ +5.5%on this news
Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases
Septerna, Inc. has commenced dosing the first participants in its Phase 1 clinical trial for SEP-631, an oral small molecule targeting MRGPRX2 to treat chronic spontaneous urticaria and other mast cell-driven diseases. The trial will assess the safety, tolerability, and pharmacokinetics of SEP-631 in healthy adults. This development aims to provide a new treatment option for patients with significant unmet needs.
Read more →SEPNSepterna Highlights Business Progress and Reports Second Quarter 2025 Financial Results Advancing Selection of Next-Generation Oral Small Molecule PTH1R Agonist for Clinical Development Initiating Phase 1 Trial for SEP-6
Septerna, Inc. has reported its second-quarter 2025 financial results and highlighted its business advancements, including the progress of its PTH1R agonist program. The company plans to select a development candidate for this program by Q3 2025 and initiate a Phase 1 clinical trial for the drug SEP-631 by early 2026. Additionally, Septerna has secured a significant collaboration with Novo Nordisk, enhancing its financial position with a $195 million upfront payment. Despite increased R&D expenses and a higher net loss, the company maintains a healthy financial outlook, projecting cash runway into 2029.
Read more →SEPNSepterna to Present at Jefferies Global Healthcare Conference
Septerna, Inc. will present at the Jefferies Global Healthcare Conference on June 5, 2025. CEO Jeffrey Finer will discuss the company's innovative approach to G protein-coupled receptor drug discovery. The live webcast will be available on their website and archived for 30 days. Septerna focuses on developing therapies in endocrinology, immunology, and metabolic diseases.
Read more →SEPNSepterna Highlights Business Progress and Reports First Quarter 2025 Financial Results Announced Global Collaboration with Novo Nordisk to Develop Oral Small Molecules for Metabolic Diseases with Over $2.2 Billion in Pot
Septerna, Inc. has announced a significant collaboration with Novo Nordisk aimed at developing oral small molecules for metabolic diseases, with potential total milestone payments exceeding $2.2 billion. This partnership is expected to bolster Septerna's financial position, which already includes $398.2 million in cash reserves. The company is poised to select a next-generation oral small molecule PTH1R agonist for clinical advancement by the end of 2025. Moreover, clinical trials for SEP-631 targeting mast cell diseases are anticipated to begin in the third quarter of 2025.
Read more →SEPN▲ +51%on this newsshared move
Septerna and Novo Nordisk to collaborate on oral small molecule medicines for obesity and other cardiometabolic diseases Collaboration combines Novo Nordisk s scientific leadership in obesity and cardiometa
Septerna, Inc. and Novo Nordisk have announced an exclusive global collaboration aimed at developing oral small molecule medicines for obesity and other cardiometabolic diseases. This partnership will leverage Novo Nordisk's scientific strengths in the field and Septerna's expertise in GPCR drug discovery. Under the agreement, Septerna could receive up to 2.2 billion USD, including upfront payments and milestone payments, while Novo Nordisk will handle all research and development expenses. The collaboration will start with four development programs targeting key GPCR receptors.
Read more →SEPNSepterna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results
Septerna, Inc. reported its fourth quarter and full year 2024 financial results, highlighting its strong financial position with $420.8 million in cash. The company is advancing its pipeline, including plans to select a next-generation PTH1R agonist for clinical trials later this year and initiate a Phase 1 trial for SEP-631 in 2025. Despite discontinuing the SEP-786 program, Septerna remains focused on developing impactful GPCR medicines.
Read more →SEPNSepterna to Present at TD Cowen 45th Annual Health Care Conference
Septerna, Inc. will present at the TD Cowen 45th Annual Health Care Conference on March 5, 2025. CEO Jeffrey Finer will discuss the company's innovative approach to GPCR drug discovery and its promising pipeline of oral small molecule therapies targeting endocrinology, immunology, and metabolic diseases. This event underscores Septerna's commitment to advancing drug development in these therapeutic areas.
Read more →SEPNSEPTERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Septerna, Inc. on Behalf of Septerna Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating Septerna, Inc. regarding potential claims on behalf of its stockholders. This follows Septerna's announcement on February 18, 2025, to halt a Phase 1 clinical trial for its drug candidate SEP-786 after observing severe cases of elevated unconjugated bilirubin. The decision led to a significant drop in the company's stock price. The investigation focuses on possible violations of federal securities laws and other business practices.
Read more →SEPN▼ -47%on this news
Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist Trial decision follows unanticipated events of elevated unconjugated bilirubin l
Septerna, Inc. announced the discontinuation of its Phase 1 clinical trial for SEP-786 due to two unanticipated severe events involving elevated levels of unconjugated bilirubin in participants. Despite this setback, the company remains optimistic about its robust PTH1R agonist program and intends to advance other candidates for hypoparathyroidism treatment. Importantly, no serious adverse events related to liver injury were reported in the trial, and the bilirubin elevations were found to be reversible. Septerna plans to progress with a next-generation candidate to regain momentum in its clinical pipeline.
Read more →SEPN▼ -47%on this news
Septerna, Inc. Investors: Company Investigated by the Portnoy Law Firm
Septerna, Inc. is facing potential legal challenges as the Portnoy Law Firm has started an investigation into possible securities fraud related to the company's operations. The firm is reaching out to investors who may have lost money in light of recent developments. On February 18, 2025, Septerna announced the discontinuation of its Phase 1 clinical trial for SEP-786, which suffered from serious adverse events. The announcement led to a significant drop of over 65% in the company's stock price during pre-market trading.
Read more →SEPN▼ -5.5%on this news
Pioneering a New Era of GPCR Drug Discovery J.P. Morgan Healthcare Conference 2025 January 2025 Nasdaq: SEPN Forward-Looking Statements This presentation contains express or implied forward looking statements of Septerna
Septerna, Inc. presented its strategic vision for GPCR drug discovery at the J.P. Morgan Healthcare Conference 2025. The company highlighted its proprietary Native Complex Platform, which aims to enhance the development of oral small molecule therapies, including SEP-786 for hypoparathyroidism. Additionally, Septerna is developing a range of GPCR-targeted candidates and anticipates significant clinical milestones in the coming years. However, the company acknowledges the risks associated with forward-looking statements regarding their future performance and project timelines.
Read more →SEPN▼ -6.8%on this news· ran to -24% by day 3
Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer
Septerna, a clinical-stage biotech company, has appointed Gil Labrucherie as its new Chief Financial Officer. Labrucherie, who has over 25 years of experience in biopharma finance and legal roles, expressed enthusiasm for contributing to Septerna’s mission in GPCR drug discovery. His previous roles include CFO at ACELYRIN and Nektar Therapeutics, highlighting his extensive background. This addition to Septerna's leadership is aimed at supporting the company's growing pipeline of therapeutic candidates.
Read more →SEPNSepterna to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Septerna, a clinical-stage biotechnology company, announced that its CEO, Dr. Jeffrey Finer, will present at the upcoming 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for January 14, 2025, and will be accessible via a live webcast on the company's website. Septerna focuses on GPCR drug discovery, utilizing its proprietary Native Complex Platform™ to advance its product pipeline in various therapeutic areas, including endocrinology and immunology.
Read more →SEPN▼ -7%on this news
Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights Deep Pipeline of GPCR Programs Focused Initially on Indications in Endocrinology, Immunology and Inflammation, and Metabolic Diseases P
Septerna, Inc. reported its third quarter 2024 financial results, highlighting the initiation of its Phase 1 clinical trial for SEP-786, an oral small molecule aimed at treating hypoparathyroidism. The company remains well-capitalized with sufficient funds to support operations through mid-2027. Septerna's pipeline, generated through its proprietary Native Complex Platform, pursues treatments across endocrinology, immunology, and metabolic diseases. However, the company faces a notable net loss and increasing operating expenses during this period.
Read more →SEPNSepterna Announces Closing of $331.2 Million Upsized Initial Public Offering
Septerna, Inc. has successfully closed its upsized initial public offering, raising $331.2 million by offering 18.4 million shares at $18.00 each. The IPO included an additional 2.4 million shares, fulfilling the underwriters' option to purchase more. Shares commenced trading on October 25, 2024, on the Nasdaq Global Market under the ticker symbol SEPN. Septerna is focused on G protein-coupled receptor drug discovery, aiming to address several therapeutic areas.
Read more →SEPNSepterna Prices Upsized Initial Public Offering
Septerna, Inc. has announced the pricing of its upsized initial public offering, which includes 16,000,000 shares offered at a price of $18.00 each. The offering is expected to raise approximately $288 million in gross proceeds and is set to close on October 28, 2024. Trading is expected to commence on the Nasdaq Global Market on October 25, 2024, under the ticker symbol 'SEPN'. Septerna focuses on developing innovative therapies using its proprietary Native Complex Platform™ for GPCR drug discovery.
Read more →Competitive Position
How SEPN ranks across every disease it competes inCompetitive Position is a premium feature
See how SEPN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial